BioMarin Pharmaceutical Revenue 2011-2026 | BMRN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue BioMarin Pharmaceutical

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
3.22 B	2.85 B	2.42 B	2.1 B	1.85 B	1.86 B	1.7 B	1.49 B	1.31 B	1.12 B	890 M	751 M	548 M	501 M	441 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.22 B	441 M	1.54 B

Quarterly Revenue BioMarin Pharmaceutical

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
825 M	745 M	-	746 M	712 M	649 M	-	581 M	595 M	596 M	-	505 M	534 M	519 M	-	409 M	502 M	486 M	-	477 M	429 M	502 M	-	461 M	388 M	401 M	-	392 M	373 M	373 M	-	334 M	317 M	304 M	-	280 M	300 M	237 M	-	209 M	250 M	203 M	-	177 M	192 M	152 M	-	137 M	137 M	128 M	-	128 M	124 M	117 M	-	113 M	111 M	109 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
825 M	109 M	370 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Heron Therapeutics HRTX	155 M	$ 0.8	2.7 %	$ 133 M	USA
Amphastar Pharmaceuticals AMPH	720 M	$ 19.23	-1.38 %	$ 899 M	USA
Altimmune ALT	41 K	$ 3.44	2.99 %	$ 303 M	USA
Aytu BioScience AYTU	66.4 M	$ 2.63	0.77 %	$ 16.5 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	720 M	$ 218.06	-1.72 %	$ 5 B	Danmark
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Incyte Corporation INCY	5.14 B	$ 90.45	-0.36 %	$ 17.7 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Inovio Pharmaceuticals INO	832 K	$ 1.61	1.9 %	$ 35.7 M	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Inventiva S.A. IVA	9.2 M	$ 6.08	5.19 %	$ 138 M	France
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Cullinan Management CGEM	18.9 M	$ 12.84	0.78 %	$ 774 M	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
KalVista Pharmaceuticals KALV	50 M	$ 16.6	-2.35 %	$ 824 M	Britain
Kamada Ltd. KMDA	180 M	$ 8.2	-0.61 %	$ 260 M	Israel
Calithera Biosciences CALA	9.75 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	21 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	32.2 M	-	-	$ 3.74 B	USA
Karyopharm Therapeutics KPTI	145 M	$ 6.66	-12.71 %	$ 812 K	USA
Keros Therapeutics KROS	244 M	$ 11.24	2.55 %	$ 418 M	USA
Checkpoint Therapeutics CKPT	41 K	-	-	$ 169 M	USA
Clovis Oncology CLVS	149 M	-	-7.23 %	$ 13 M	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Longeveron LGVN	1.2 M	$ 0.95	-2.71 %	$ 16.7 B	USA
Denali Therapeutics DNLI	331 M	$ 21.09	4.56 %	$ 3.47 B	USA
Arbutus Biopharma Corporation ABUS	18.1 M	$ 4.42	4.25 %	$ 734 M	Canada